Edwards Lifesciences Corporation (NYSE:EW)‘s stock had its “equal weight” rating restated by analysts at Barclays PLC in a note issued to investors on Saturday. They currently have a $120.00 price objective on the medical research company’s stock. Barclays PLC’s price objective would indicate a potential upside of 9.78% from the company’s current price.

A number of other analysts also recently commented on the company. William Blair reaffirmed an “outperform” rating on shares of Edwards Lifesciences Corporation in a research report on Monday, August 28th. BMO Capital Markets reaffirmed a “buy” rating and set a $132.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, September 1st. Canaccord Genuity reissued a “buy” rating and set a $150.00 price objective on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research raised Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $130.00 price objective for the company in a report on Tuesday, July 18th. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $130.00 price objective on shares of Edwards Lifesciences Corporation in a report on Friday, September 1st. Seven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $120.75.

Edwards Lifesciences Corporation (NYSE EW) opened at 109.31 on Friday. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The stock’s 50 day moving average price is $113.80 and its 200 day moving average price is $109.37. The company has a market capitalization of $23.08 billion, a P/E ratio of 33.15 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, beating the Zacks’ consensus estimate of $0.88 by $0.20. The company had revenue of $842.00 million during the quarter, compared to the consensus estimate of $839.16 million. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. Edwards Lifesciences Corporation’s revenue was up 10.9% on a year-over-year basis. During the same period last year, the business posted $0.76 earnings per share. Analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Edwards Lifesciences Corporation’s (EW) “Equal Weight” Rating Reiterated at Barclays PLC” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/30/edwards-lifesciences-corporations-ew-equal-weight-rating-reiterated-at-barclays-plc.html.

In other Edwards Lifesciences Corporation news, CEO Michael A. Mussallem sold 32,900 shares of the firm’s stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $114.80, for a total transaction of $3,776,920.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction dated Friday, July 28th. The shares were sold at an average price of $114.68, for a total value of $607,804.00. The disclosure for this sale can be found here. Insiders have sold 176,901 shares of company stock valued at $20,191,196 in the last three months. 2.13% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EW. BlackRock Inc. raised its position in Edwards Lifesciences Corporation by 2,184.9% during the first quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock valued at $1,317,326,000 after purchasing an additional 13,390,818 shares in the last quarter. Bank of New York Mellon Corp raised its position in Edwards Lifesciences Corporation by 161.7% during the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock valued at $627,207,000 after purchasing an additional 3,277,726 shares in the last quarter. Egerton Capital UK LLP purchased a new stake in Edwards Lifesciences Corporation during the second quarter valued at about $217,805,000. Alliancebernstein L.P. raised its position in Edwards Lifesciences Corporation by 29.8% during the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock valued at $598,890,000 after purchasing an additional 1,459,921 shares in the last quarter. Finally, Koch Industries Inc. raised its position in Edwards Lifesciences Corporation by 28,363.1% during the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock valued at $1,386,000 after purchasing an additional 1,392,345 shares in the last quarter. Institutional investors and hedge funds own 82.08% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.